Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) continues to be the most common cause of cognitive and motor alterations in the aging population. Accumulation of amyloid β (Aβ)-protein oligomers and the microtubule associated protein-TAU might be responsible for the neurological damage. We have previously shown that Cerebrolysin (CBL) reduces the synaptic and behavioral deficits in amyloid precursor protein (APP) transgenic (tg) mice by decreasing APP phosphorylation via modulation of glycogen synthase kinase-3β (GSK3β) and cyclin-dependent kinase-5 (CDK5) activity. These kinases also regulate TAU phosphorylation and are involved in promoting neurofibrillary pathology. In order to investigate the neuroprotective effects of CBL on TAU pathology, a new model for neurofibrillary alterations was developed using somatic gene transfer with adeno-associated virus (AAV2)-mutant (mut) TAU (P301L). The Thy1-APP tg mice (3 m/o) received bilateral injections of AAV2-mutTAU or AAV2-GFP, into the hippocampus. After 3 months, compared to non-tg controls, in APP tg mice intra-hippocampal injections with AAV2-mutTAU resulted in localized increased accumulation of phosphorylated TAU and neurodegeneration. Compared with vehicle controls, treatment with CBL in APP tg injected with AAV2-mutTAU resulted in a significant decrease in the levels of TAU phosphorylation at critical sites dependent on GSK3β and CDK5 activity. This was accompanied by amelioration of the neurodegenerative alterations in the hippocampus. This study supports the concept that the neuroprotective effects of CBL may involve the reduction of TAU phosphorylation by regulating kinase activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376 · cited 1×
“The neurodegenerative process in the initial stages of AD targets the synaptic terminals [11, 41] and then propagates to axons and dendrites leading to neuronal dysfunction and eventually to neuronal death in later stages of the disease [24].”
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938 · cited 1×
“This synaptic pathology in the hippocampus results in memory and learning deWcits characteristic of AD [85].”
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · cited 3×
“Though in vitro studies have suggested that CBL treatment reduces TAU phosphorylation [58, 80], it remains unclear whether CBL might reduce neuroWbrillary pathology in vivo.”
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 1×
“Sections were imaged with the LSCM (MRC1024, BioRad) as described previously [47] and digital images were analyzed with the NIH Image 1.”
Self-citationAPP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644 · cited 1×
“Although the precise mechanisms leading to neurodegeneration in AD are not completely understood, recent studies suggest that alterations in the processing of amyloid precursor protein (APP), resulting in the accumulation of amyloid-β protein (Aβ) and APP C-terminal products, might play a key role in the pathogenesis…”
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 2×
“Moreover, the P301L mutant of TAU which is associated with familial forms of fronto-temporal dementia [35, 56] has been shown to promote neuroWbrillary”
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 3×
“As Aβ is thought to enhance TAU pathology [20], CBL’s effects on the reduction of TAU pathology in the combined model may be related to the effects of CBL at decreasing Aβ production.”
Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior
Selkoe, D. J. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.02.016 · Cited by 1,038
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms
Andorfer, C., Kress, Y., Espinoza, M., De Silva, R., Tucker, K. L., Barde, Y., Duff, K., & Davies, P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01879.x · Cited by 722
Cited by
Practical considerations for choosing a mouse model of Alzheimer’s disease
Jankowsky, J. L., & Zheng, H. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0231-7 · Cited by 449
“huMAPT4R1N (P301L) CMV AAV2 adult mouse [216]”
Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice
Jolivalt, C. G., Hurford, R., Lee, C. A., Dumaop, W., Rockenstein, E., & Masliah, E. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.11.005 · Cited by 177
Self-citationRole of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease
Shri, S. R., Manandhar, S., Nayak, Y., & Pai, K. S. R. (2023) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2023.071 · Cited by 71
The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration
Deger, J. M., Gerson, J. E., & Kayed, R. (2015) · Aging Cell · doi:10.1111/acel.12359 · Cited by 69
“In fact, some studies suggest that tau may be neuroprotective (Ubhi et al., 2009).”
BackgroundValera, E., Spencer, B., Mott, J., Trejo, M., Adame, A., Mante, M., Rockenstein, E., Troncoso, J. C., Beach, T. G., Masliah, E., et al. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00329 · Cited by 55
“Briefly, as previously described (Ubhi et al., 2009), mice were placed under anesthesia on a Koft stereotaxic apparatus and coordinates (AP = +1 mm; L = ±1.5 mm, DV = −3.0 mm) were determined as per the Franklin and Paxinos Atlas.”
MethodInfluentialSelf-citationBritschgi, M., Takeda-Uchimura, Y., Rockenstein, E., Johns, H., Masliah, E., & Wyss-Coray, T. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-220 · Cited by 45
“Two microliters of each AAV2 (tau or GFP; 8 × 10(12) vg/ml [12]) were injected with a 10 μl Hamilton syringe for 2 min at a rate of 1 μl/min in a nanoinjector system.”
MethodSelf-citation
Metadata
- Authors
- Ubhi, K., Rockenstein, E., Doppler, E., Mante, M., Adame, A., Patrick, C., Trejo, M., Crews, L., Paulino, A., Moessler, H., & Masliah, E.
- Venue
- Acta Neuropathologica
- Published
- 2009-02-28
- Volume
- 117
- Issue
- 6
- Pages
- 699-712
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2135724524
- Cited by
- 42
- References
- 24
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.